Valderm
Lyngby
About Valderm
Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyperproliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $3.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2007)
- Website: valderm.dk
- Phone: +45 30 13 85 81
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/valderm-2039632 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.